Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM5C | P41229 | 5/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.46 |
| ▸ | KDM5A | P29375 | 2/20 | 0.46 |
| ▸ | KDM5D | Q9BY66 | 1/20 | 0.46 |
| ▸ | KDM4B | O94953 | 2/20 | 0.45 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8594535 | 0.85 | CYP1A2 (0.47) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| SCHEMBL12252467 | 0.85 | GABRP (0.58) | CYP1A2POLBKDM4EKDM5CKDM5B | |
| SCHEMBL30607268 | 0.85 | CYP1A2 (0.47) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| SCHEMBL7668183 | 0.85 | CYP1A2 (0.47) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| Hydrochloric Acid SCHEMBL1244313 | 0.83 | GABRP (0.56) | CYP1A2POLBKDM4EKDM5CKDM5B | |
| SCHEMBL15991431 | 0.83 | CYP1A2 (0.46) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| SCHEMBL5566822 | 0.83 | CYP1A2 (0.46) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| 2-Ethylisonicotinamide SCHEMBL2606610 | 0.83 | CYP1A2 (0.69) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| SCHEMBL5147899 | 0.81 | TSHR (0.51) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| SCHEMBL17873933 | 0.80 | KDM4E (0.73) | CYP1A2POLBKDM4ELMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119633134-A | Bionic naringenin polydopamine nanoparticle and application thereof | 北京大学人民医院 | 2025-03-18 | — | — | CN | claimed |
| CN-119633134-A | Bionic naringenin polydopamine nanoparticle and application thereof | 北京大学人民医院 | 2025-03-18 | — | — | CN | disclosed |
| EP-1762567-B1 | Pyrazole derivatives for treating HIV | PFIZER LTD (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| CN-100408564-C | Pyrazole derivatives for treating HIV | PFIZER LTD (US) | 2008-08-06 | — | — | CN | disclosed |
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | disclosed |
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | disclosed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | disclosed |
| US-7109228-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060020012-A1 | Pyrazole derivatives | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
| CN-1514828-A | Pyrazole derivatives for treating HIV | — | 2004-07-21 | — | — | CN | disclosed |
| EP-1377556-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | disclosed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | disclosed |
| WO-2002085860-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LIMITED (GB) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | RRM2B, REV1, RRM2 | CYP1A2 348/4885POLB 40/4885KDM4E 1500/4885 |
| US-20060020012-A1 | Pyrazole derivatives | PDCD11, RTF1, REV1 | CYP1A2 400/4885POLB 93/4885KDM4E 1943/4885 |
| US-20120029192-A1 | Pyrazole Derivatives | POLRMT, PDCD11, DPYD | CYP1A2 307/4885POLB 41/4885KDM4E 2614/4885 |
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | CYP1A2 173/4885POLB 66/4885KDM4E 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.